Third Harmonic Bio to Join Jefferies Global Healthcare Conference

Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company in the clinical development stage, is dedicated to pioneering new treatments for inflammatory diseases affecting the skin, respiratory system, and gastrointestinal tract. On May 28, 2024, the company announced that its CEO, Natalie Holles, would take part in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2024, at 7:30 a.m. ET. This announcement underscores the company's ongoing efforts to engage with the healthcare investment community and share advancements in its research and development programs.

The live audio webcast of the event will be accessible through the Investors & Media section of the Third Harmonic Bio website. For those unable to attend the live session, an archived replay will be available for 90 days after the event, providing extended access to the company's insights and future directions.

Third Harmonic Bio’s mission is to transform the treatment landscape for inflammatory diseases by developing novel, highly selective small-molecule inhibitors targeting KIT, a critical cell surface receptor that regulates mast cell functions and survival. Mast cells play a significant role in various inflammatory conditions, and inhibiting KIT has shown promise in modulating these cells' activities. The company’s approach could potentially offer new therapeutic options for a range of diseases mediated by mast cell activity.

The company's leading drug candidate, THB335, is a titratable, oral small-molecule inhibitor currently undergoing Phase 1 clinical trials. This drug aims to provide a precise and adjustable treatment option for patients, potentially improving efficacy and safety profiles compared to existing therapies. Early clinical results have indicated that KIT inhibition could significantly impact the treatment of mast-cell-mediated inflammatory diseases, suggesting a breakthrough in a field with substantial unmet medical needs.

As Third Harmonic Bio continues to advance its research, the participation of CEO Natalie Holles in prominent industry conferences like the Jefferies Global Healthcare Conference highlights the company's commitment to transparency and collaboration with the broader scientific and investment communities. Engaging in such high-profile events allows the company to showcase its innovations, attract potential partners, and secure investor confidence.

In summary, Third Harmonic Bio is at the forefront of developing next-generation treatments for various inflammatory diseases through its innovative approach to KIT inhibition. The upcoming fireside chat at the Jefferies Global Healthcare Conference represents an opportunity for the company to disseminate its progress and future objectives to a wider audience, reinforcing its position as a leader in the biopharmaceutical industry.